Spring til hovednavigatio
Spring til søgning
Spring til hovedindhold
Sorter
Keyphrases
5 Degrees of Freedom
10%
95% Confidence Interval
13%
Abduction-adduction
16%
Activities of Daily Living
8%
Acute Ischemic Stroke
29%
Acute Onset
10%
Acute Stroke
18%
Adjuvant Therapy
6%
Adverse Events
8%
All-cause Mortality
7%
Alzheimer's Disease
21%
Amyotrophic Lateral Sclerosis
55%
Atrial Fibrillation
17%
Axon Terminal
6%
Calcium Level
10%
Cardiac Magnetic Resonance Imaging (cMRI)
9%
Chronic Inflammatory Demyelinating Polyneuropathy
27%
Cladribine
10%
Clinical Evaluation
8%
Clinical Outcomes
9%
Clinical Trials
7%
Cognitive Function
17%
Cognitive Impairment
8%
Confidence Interval
8%
Cortical Excitability
6%
Danish National Patient Registry
6%
Dementia Diagnosis
6%
Denmark
44%
Diabetes
8%
Diagnostic Criteria
13%
Dimethyl Fumarate
11%
Disability
7%
Disease Activity
10%
Disease-modifying Therapy
15%
Early Alzheimer's Disease
11%
Early Breast Cancer
10%
Endovascular Treatment
10%
Epilepsy
9%
Everyday Life
10%
Exercise Effect
6%
Fingolimod
15%
Hazard Ratio
11%
Healthcare Professionals
8%
High-intensity Exercise
6%
Hospital Discharge Records
6%
Hybrid Robot
10%
Incidence Rate
8%
Intracerebral Hemorrhage
13%
Intracranial Tumor
7%
Intravenous Thrombolysis
10%
Ischemic Stroke
16%
Ischemic Stroke Recurrence
7%
Jutland
7%
Levetiracetam
6%
Mild Alzheimer's Disease
7%
Mild Cognitive Impairment
7%
Minor Stroke
21%
Modified Rankin Scale
6%
Moyamoya Disease
10%
MS Patients
8%
Multiple Sclerosis
81%
Multiple Sclerosis Treatment
15%
Natalizumab
20%
National Cohort Study
49%
Nested Case-control Study
11%
Neuropathic Pain
14%
Ocrelizumab
17%
Odds Ratio
7%
Parkinson's Disease
10%
Passive Transfer
10%
Patient Experience
17%
Performance Improvement
10%
Phase Coherence
10%
Pregabalin
8%
Prognostic Factors
11%
Progressive multiple Sclerosis
7%
Progressive Paralysis
10%
Prospective Cohort Study
10%
Quality of Life
25%
Randomized Controlled Trial
20%
Relapsing-remitting multiple Sclerosis
27%
Remote Ischemic Preconditioning
21%
Robot Interface
10%
Sham
7%
Stroke Risk
8%
Subcutaneous Immunoglobulin
27%
Subgroup Analysis
11%
Tapering off
8%
Tendon-driven
10%
Teriflunomide
16%
Thrombolysis
9%
Thrombolytic Therapy
6%
Tongue
21%
Transient Ischemic Attack
41%
Treatment Duration
6%
Upper Limb Exoskeleton
16%
White Matter Hyperintensities
6%
Wrist
16%
Medicine and Dentistry
Adduction
16%
Adverse Event
8%
Allergic Encephalitis
10%
Alteplase
14%
Alzheimer's Disease
18%
Amyotrophic Lateral Sclerosis
41%
Angiography
5%
Apoplexy
100%
Atrial Fibrillation
9%
Autoimmune Disease
6%
Autoimmunity
12%
Blood Clot Lysis
39%
Brain Ischemia
81%
Capillary
6%
Carbon 13
5%
Cardiovascular System
6%
Case-Control Study
5%
Central Nervous System
7%
Cerebral Hemorrhage
7%
Cerebrospinal Fluid
7%
Cerebrum
7%
CHA2DS2-VASc Score
7%
Chronic Inflammatory Demyelinating Polyneuropathy
21%
Clinical Trial
12%
Cognitive Rehabilitation
6%
Cohort Analysis
51%
Comorbidity
12%
Diabetes
13%
Disease Modifying Therapy
8%
Diseases
21%
Electroencephalography
10%
Electromyography
8%
Encephalitis
5%
Endovascular Surgery
10%
Epilepsy
8%
Epileptic Seizure
6%
Etiology
5%
Evoked Cortical Response
6%
Executive Function
6%
Fibromyalgia
10%
Fumaric Acid Dimethyl Ester
16%
Functional Magnetic Resonance Imaging
10%
Gabapentin
6%
Hazard Ratio
15%
Hydrocephalus
7%
Immunoglobulin
27%
Immunosuppressive Treatment
6%
Immunotherapy
5%
Infarction
7%
Insulin Dependent Diabetes Mellitus
22%
Levetiracetam
7%
Long-Term Outcome
7%
Magnetic Resonance Imaging
35%
Metabolite
9%
Modified Rankin Scale
16%
Motor Neuron
5%
Multiple Sclerosis
52%
Muscle Strength
10%
Myasthenia gravis
17%
Myopathy
16%
National Institutes of Health Stroke Scale
7%
Neurodevelopmental Disorder
6%
Neurology
9%
Neuropathic Pain
13%
Neuropathy
9%
Normal Pressure Hydrocephalus
16%
Ocrelizumab
5%
Odds Ratio
13%
Oral
6%
Paralysis
6%
Paraneoplastic Cerebellar Degeneration
6%
Parkinson's Disease
21%
Patient Referral
9%
Placebo
27%
Polyneuropathy
20%
Pregabalin
9%
Prevalence
11%
Primary Motor Cortex
7%
Prospective Cohort Study
10%
Pyruvic Acid
5%
Quality of Life
16%
Randomized Clinical Trials
6%
Randomized Controlled Trial
18%
Recurrent Disease
9%
Sequela
10%
Sex Differences
6%
Stereotypic Movement Disorder
7%
Subcutaneous Injection
5%
Subgroup Analysis
6%
Synaptic Transmission
8%
Teriflunomide
16%
Thrombocytopenia
5%
Tongue
16%
Transcranial Magnetic Stimulation
7%
Transient Ischemic Attack
15%
Treatment Duration
6%
Upper Limb
23%
Ventriculomegaly
6%
Walk Test
5%
Neuroscience
Alteplase
8%
Alzheimer's Disease
38%
Amyloid Protein
6%
Amyotrophic Lateral Sclerosis
52%
Anticonvulsant
7%
Apolipoprotein E
5%
Ataxia
5%
Atrial Fibrillation
13%
Axon
7%
Bicarbonate
5%
Biological Marker
7%
Blood Plasma
11%
Body Mass Index
5%
Brain Ischemia
59%
Brain-Computer Interface
5%
Cerebral Amyloid Angiopathy
5%
Cerebral Hemorrhage
20%
Cerebrovascular Accident
88%
Citalopram
5%
Clinical Neurophysiology
5%
Cognitive Decline
6%
Cognitive Disorders
15%
Comorbidity
10%
Computed Tomography
6%
Contrast Medium
5%
Creatine
8%
Dementia with Lewy Bodies
5%
Diabetic Neuropathy
11%
Electrical Brain Stimulation
5%
Electroencephalography
16%
Electromyography
7%
Embolic Stroke
5%
Epilepsy
14%
Evoked Cortical Response
7%
Excitability
7%
Expanded Disability Status Scale
9%
Familial Hemiplegic Migraine
5%
Fibromyalgia
10%
Fingolimod
8%
Functional Magnetic Resonance Imaging
10%
Gait
8%
Gait Disorder
5%
Gamma-Aminobutyric Acid
6%
Glucocorticoid
7%
Granule Cell
5%
Gray Matter
5%
Gray Matter Volume
7%
High Density Lipoprotein Cholesterol
5%
Histopathology
5%
Hydrocephalus
7%
Hypertension
5%
Immunosuppressive Drug
5%
Immunotherapy
12%
Interleukin 6
5%
Intravenous Immunoglobulin
19%
Lacunar Stroke
5%
Lacune
5%
Levetiracetam
7%
Liraglutide
5%
Magnetic Resonance Imaging
39%
Memory Test
5%
Migraine
5%
Motor Unit
6%
Multiple Sclerosis
67%
Muscle Disorder
16%
Myasthenia gravis
5%
Natalizumab
10%
Neurofilament
5%
Neurofilament Light Chain
5%
Neuropathic Pain
13%
Neuropathy
22%
Neuroprotective Agent
6%
Neuroregeneration
5%
Normal Pressure Hydrocephalus
10%
Ocrelizumab
10%
Omega 3 Fatty Acid
5%
Parkinson's Disease
16%
Placebo
30%
Polyneuropathy
42%
Positron Emission Tomography
8%
Primary Motor Cortex
12%
Psychopathology
16%
Quality of Life
13%
Randomized Controlled Trial
24%
Relapsing Remitting Multiple Sclerosis
26%
Rituximab
5%
Secondary Progressive Multiple Sclerosis
6%
Spinal Cord Injury
5%
Spinocerebellar Ataxia
5%
Subdural Hematoma
8%
Subdural Space
5%
Synaptic Transmission
12%
Synaptic Vesicle
8%
Teriflunomide
16%
Theophylline
10%
Thrombolytic Drug
10%
Transcranial Direct Current Stimulation
5%
Transcranial Magnetic Stimulation
23%
Transient Ischemic Attack
19%
Upper Motor Neuron
8%